Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversitaire Ziekenhuizen KU Leuven
About this trial
The goal of this observational study is to learn more about the real-world efficacy of biologics in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). All patients who are 18 years or older, who have CRSwNP and are eligible for reimbursement of a biological for the indication of CRSwNP can be included.
The main question is the efficacy of biologics in real life after 24 weeks. The main focus are patient reported outcomes measured via several questionnaires and the nasal polyp score, scored with nasal endoscopy.
Eligibility criteria
Qualifiers
Participant must be at least 18 years of age at the time of signing the informed consent.
Capable of giving signed informed consent.
Participants should have CRSwNP.
Participants should fulfil the reimbursement criteria for their prescribed biological (omalizumab, mepolizumab and/or dupilumab).
Disqualifiers
None
Trial design
Treatments tested in this trial
- Omalizumab
- Dupilumab
- Mepolizumab 100 mg
Treatment groups
No treatment groups listed
Locations
8Onze Lieve Vrouw hospital Aalst9300, Aalst Belgium
General hospital Sint-Jan Bruges8000, Bruges Belgium
University hospital Saint-Luc1200, Brussels Belgium
University hospital of Antwerp2650, Edegem Belgium
Sponsors and collaborators
Universitaire Ziekenhuizen KU Leuven
Lead sponsor
Source ClinicalTrials.gov